Neuroendocrinology Letters, Home
Neuroendocrinology Letters, Vol. 20 Nos. 3/4 Contents
Contact us
Subscription info
Neuroendocrinology›Letters incl. Psychoneuroimmunology & Chronobiology. Researh Papers.
ISSN›0172Ů780X Copyright›©›1999 Neuroendocrinology›Letters
pil_red_L.gif (318 bytes) Back

NEL VOL. 20 3/4

1999; 20:237–244

New analogs of somatostatin: inhibiting effectively GH, glucagon and insulin levels
by Boguslawa Baranowska, Malgorzata Radzikowska, Elzbieta Wasilewska-Dziubinska, Artur Plonowski, Krzysztof Roguski, Anna Legowska & JŘzef Przybylski

Key words:
somatostatin analogs, growth hormone, insulin, glucagon

The in vivo effects of three new analogs of somatostatin (ASS-51, ASS-52 and ASS-53 analogs) on GH, insulin and glucagon were studied in WKY rats. The solid phase method was used for the synthesis of ASS. Octreotide and ASS were given iv. in a dose of 0.05 Ķg/kg per animal in a time-dependent manner. ASS-52 and ASS-53 were longer acting and more potent somatostatin analogs when compared to octreotide in producing the inhibition of GH. ASS-51 was found to be the most potent and selective inhibitor of insulin and glucagon release. Our results show that the increased inhibitory effect and the higher selectivity of the new somatostatin analogs may result from the differences in their chemical structure.
ASS-52 is most active in inhibiting GH release. The mechanism by which ASS-52 inhibits preferentially GH release may involve the opioid system and the activation of GABA-ergic receptors.
     In studies in vitro ASS-52 inhibited GH release from pituitary cells’ culture.

Copyright © Neuroendocrinology Letters 1999
All rights reserved. No part may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or ortherwise, without prior written permission from the Editor-in-Chief.